证券代码：605507 证券简称：国邦医药 公告编号：2024-056 国邦医药集团股份有限公司 关于以集中竞价交易方式回购股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/1/27 | | | --- | --- | --- | | 回购方案实施期限 | 董事会审议通过后 个月 12 | | | 预计回购金额 | 1 亿元~2 | 亿元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | □用于转换公司可转债 □为维护公司价值及股东权益 | | | 累计已回购股数 | 6,212,400 | 股 | | 累计已回购股数占总股本比 | 1.11% | | | 例 | | | | 累计已回购金额 | 100,995,168.00 元 | | | 实际回购价格区间 | 元/股~18.66 元/股 13.05 | | 一、回购股份的基本情况 国邦医药集团股份有限公司（以下简称"公司"）于 2024 年 1 月 26 日召开第二 届董事 ...

证券代码：605507 证券简称：国邦医药 公告编号：2024-055 重要内容提示： 会议召开时间：2024 年 9 月 23 日（星期一）上午 9:00-10:00 会议召开地点： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 9 月 12 日（星期四）至 9 月 22 日（星期日）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 info@gbgcn.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 国邦医药集团股份有限公司（以下简称"公司"）已于 2024 年 8 月 30 日发布 公司 2024 年半年度报告，为便于广大投资者更全面深入地了解公司 2024 年半年 度的经营成果、财务状况，公司计划于 2024 年 9 月 23 日（星期一）上午 9:00-10:00 举行 2024 年半年度业绩说明会，就投资者关心的问题进行交流。 一、业绩说明会类型 本次业绩说明会以网络互动形式召开，公司将针对 2024 年半 ...

[Table_StockInfo] 2024 年 09 月 04 日 证券研究报告•2024 年半年报点评 买入 （维持） 当前价：18.92 元 国邦医药（605507）医药生物 目标价：——元（6 个月） 医药业务回暖，Q2 业绩优秀 [Table_Summary 业绩总结：公司发布 ] 2024半年度报告，2024H1公司实现营收 28.92亿，同比 增长 2.94%；归母净利润 4.05 亿，同比增长 13.18%。其中 24Q2 单季度实现 营收 15.54亿，同比增长 11.01%；归母净利润 2.06亿，同比增长 26.42%；扣 非归母净利润 2.02 亿，同比增长 21.99%。 点评：原料药及中间体齐发力，逆势增长巩固市场地位。上半年公司医药板块 实现营业收入 20.36亿元，同比增长 9.46%，占总收入的 70%。公司上半年 26 个主要产品中有 20个实现了销售量增长，尽管整体需求尚未完全复苏，但公司 通过优化生产工艺和提升产品竞争力，逆势实现了增长。动保板块实现收入 8.2 亿元，同比下降约 10%，但销量大幅提升，成本端有所下降。 养殖业周期反转或带动动保板块量价齐升。2024 ...

[Table_StockInfo] 2024 年 09 月 04 日 证券研究报告•2024 年半年报点评 买入 （维持） 当前价：18.92 元 国邦医药（605507）医药生物 目标价：——元（6 个月） 医药业务回暖，Q2 业绩优秀 [Table_Summary 业绩总结：公司发布 ] 2024半年度报告，2024H1公司实现营收 28.92亿，同比 增长 2.94%；归母净利润 4.05 亿，同比增长 13.18%。其中 24Q2 单季度实现 营收 15.54亿，同比增长 11.01%；归母净利润 2.06亿，同比增长 26.42%；扣 非归母净利润 2.02 亿，同比增长 21.99%。 点评：原料药及中间体齐发力，逆势增长巩固市场地位。上半年公司医药板块 实现营业收入 20.36亿元，同比增长 9.46%，占总收入的 70%。公司上半年 26 个主要产品中有 20个实现了销售量增长，尽管整体需求尚未完全复苏，但公司 通过优化生产工艺和提升产品竞争力，逆势实现了增长。动保板块实现收入 8.2 亿元，同比下降约 10%，但销量大幅提升，成本端有所下降。 养殖业周期反转或带动动保板块量价齐升。2024 ...

证券代码：605507 证券简称：国邦医药 □ 特定对象调研 □ 分析师会议 □ 媒体采访 √ 业绩说明会 投资者关系活 □ 新闻发布会 □ 路演活动 动类别 □ 现场参观 □ 其他（电话会议） 国邦医药集团股份有限公司 投资者关系活动记录表 编号：2024-001 | --- | --- | --- | --- | --- | --- | |--------------|----------------------------------------------------------|-------|-------|--------------------------------------------------------|-------| | | | | | | | | 参与单位名称 | 中信证券（韩世通、王凯旋、王郑洋）；华创证券（王宏雨）； | | | | | | 及人员姓名 | 开源证券（阮帅）；银河证券（孙怡）；首创证券（王斌）；国 | | | | | | | 盛证券（胡偌碧）；东吴证券（徐梓煜）；中泰证券（祝嘉琦、 | | | | | | | 李雨蓓）；中信建投（赖俊勇）；太平洋医药（周豫 ...

证券代码：605507 证券简称：国邦医药 公告编号：2024-054 国邦医药集团股份有限公司 关于以集中竞价交易方式回购股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/1/27 | | | --- | --- | --- | | 回购方案实施期限 | 董事会审议通过后 个月 12 | | | 预计回购金额 | 1 亿元~2 | 亿元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | □用于转换公司可转债 □为维护公司价值及股东权益 | | | 累计已回购股数 | 6,212,400 | 股 | | 累计已回购股数占总股本比 | 1.11% | | | 例 | | | | 累计已回购金额 | 100,995,168.00 元 | | | 实际回购价格区间 | 元/股~18.66 元/股 13.05 | | 一、回购股份的基本情况 国邦医药集团股份有限公司（以下简称"公司"）于 2024 年 1 月 26 日召开第二 届董事 ...

公 司 研 究 2024 年 08 月 27 日 公司深度研究 买入/维持 国邦医药(605507) 昨收盘:16.61 医药生物 医药业务回暖，动保业务弹性可期 | --- | --- | --- | --- | --- | |-------|------------------------------------------------------------|-----------------|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Performance - The company's operating revenue for the first half of 2024 was CNY 2,892,356,514.66, representing a 2.94% increase compared to CNY 2,809,720,242.62 in the same period last year[11]. - The net profit attributable to shareholders for the first half of 2024 was CNY 404,597,903.42, which is a 13.18% increase from CNY 357,470,775.26 in the previous year[11]. - The net profit after deducting non-recurring gains and losses was CNY 395,225,027.11, reflecting a 10.44% increase from CNY 357,850,586.20 year-on-year[11]. - The basic earnings per share for the first half of 2024 was CNY 0.73, up 14.06% from CNY 0.64 in the same period last year[12]. - The weighted average return on net assets increased to 5.34%, up from 4.91% in the previous year, marking an increase of 0.43 percentage points[12]. - The company achieved operating revenue of CNY 2.89 billion in the first half of 2024, representing a year-on-year growth of 2.94%[33]. - The net profit attributable to shareholders reached CNY 405 million, an increase of 13.18% compared to the same period last year[33]. - The total profit for the first half of 2024 was ¥464.09 million, an increase from ¥412.91 million in the first half of 2023, marking a growth of about 12.4%[95]. Cash Flow and Assets - The net cash flow from operating activities decreased significantly by 881.67%, resulting in a negative cash flow of CNY -249,983,820.26, primarily due to increased cash payments for goods and higher prepayments for raw materials[12]. - The total assets at the end of the reporting period were CNY 10,086,961,285.49, a decrease of 2.65% compared to CNY 10,361,635,348.92 at the end of the previous year[11]. - The cash flow from operating activities showed a significant decline, with a net outflow of CNY 249.98 million, down 881.67% year-on-year[33]. - Cash and cash equivalents decreased to CNY 1,341,322,469.77 from CNY 2,094,158,957.59, representing a significant decline of approximately 36.0%[87]. - The company's total liabilities decreased to CNY 2,511,004,909.10 from CNY 2,924,446,559.57, a reduction of approximately 14.1%[89]. - The company's current assets totaled CNY 5,113,132,959.29, down from CNY 5,443,146,893.29, indicating a decrease of about 6.1%[87]. Investments and Projects - The company is advancing key projects, including a 70,000-ton pharmaceutical intermediate project and a 1,420-ton pharmaceutical raw material project, which are progressing as planned[30]. - The cumulative investment in the pharmaceutical industry chain projects has reached 20,117.04 million, achieving a completion rate of 100.57%[74]. - The company has invested 6,139.93 million in the new animal health raw material project, with a completion rate of 100.71%[74]. - The investment in the pharmaceutical formulation project is 11,151.14 million, with a completion rate of 70.47%[74]. Market Presence and Strategy - The company operates in 115 countries and regions globally, with over 3,000 sales customers, including major pharmaceutical firms like Bayer and Abbott[15]. - The company aims to achieve 30 globally leading scaled products and 80 products in regular production as part of its mid-to-long-term strategic goals[21]. - The company emphasizes a dual strategy of horizontal multi-product replication and vertical industry chain extension to drive growth[21]. - The company is focusing on expanding its market presence and enhancing product competitiveness through strategic collaborations in the animal health sector[30]. Environmental and Regulatory Compliance - The company is committed to environmental protection and has increased investments in green production in response to stricter regulatory requirements related to carbon neutrality[45]. - The company has implemented nine sets of RTO waste gas treatment facilities, with a total processing capacity of 381,000 m³/h[28]. - The company has reported zero environmental incidents throughout the year, demonstrating effective control of environmental and safety risks[53]. - The company has established a comprehensive environmental monitoring management capability, ensuring timely reporting of monitoring information to environmental protection authorities[54]. Shareholder and Equity Management - The controlling shareholder and actual controller committed to not transferring or entrusting the management of shares for 36 months post-IPO, with a lock-up period extending if stock prices fall below the IPO price[59]. - The company has a structured plan for shareholder equity management, including limits on share reductions and mandatory disclosures for any planned sales[60]. - The total number of ordinary shareholders reached 29,264 by the end of the reporting period[79]. - The total share capital of the company is 558,823,500 shares, with 46.01% being restricted shares and 53.99% being tradable shares[78]. Risks and Challenges - There are no significant risks that have materially affected the company's operations during the reporting period[2]. - The company faces risks from industry policy changes, particularly in the pharmaceutical sector, and plans to adapt product strategies accordingly to maintain competitive advantages[44]. - The company exports products to 115 countries and regions across six continents, exposing it to foreign exchange rate fluctuations that could affect sales revenue and profitability[45]. Research and Development - The company has established research institutes to enhance its independent innovation capabilities, employing over 530 R&D personnel[28]. - R&D expenses for the first half of 2024 were approximately ¥92.96 million, a decrease from ¥97.44 million in the same period of 2023, reflecting a reduction of about 4.8%[95]. - The company holds 203 authorized patents, including 194 invention patents, enhancing its competitive edge in R&D[28]. Accounting and Financial Reporting - The financial statements are prepared based on the going concern assumption, ensuring the company's ability to continue its operations[119]. - The company adheres to the accounting standards set by the Ministry of Finance, ensuring that the financial statements reflect a true and complete view of its financial status[120]. - The company recognizes revenue when control of goods or services is transferred to customers, which is when customers can direct the use and obtain almost all economic benefits[176].

证券代码：605507 证券简称：国邦医药 公告编号：2024-051 国邦医药集团股份有限公司 第二届董事会第九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 国邦医药集团股份有限公司(以下简称"公司")第二届董事会第九次会议于 2024 年 8 月 19 日以书面及邮件等方式发出通知和会议材料，并于 2024 年 8 月 29 日在公司会议室以现场结合通讯的方式召开。会议应出席董事 9 人，实际出 席会议的董事 9 人。会议由董事长邱家军先生主持，监事、高管列席。本次董事 会会议的召集、召开和表决程序符合有关法律、行政法规、部门规章、规范性文 件和《公司章程》的规定。经会议审议，全体董事审议通过了如下议案。 具体内容详见公司披露于上海证券交易所网站（www.sse.com.cn）的《国邦 医药 2024 年半年度报告》及《国邦医药 2024 年半年度报告摘要》。 在提交本次董事会审议前，本议案已经董事会审计委员会审议通过。 （二）审议通过《关于 2024 年半年度募集资金存放与使用情 ...

证券代码：605507 证券简称：国邦医药 公告编号：2024-052 国邦医药集团股份有限公司 第二届监事会第八次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 监事会会议召开情况 国邦医药集团股份有限公司(以下简称"公司")第二届监事会第八次会议于 2024 年 8 月 19 日以书面及邮件等方式发出通知和会议材料，并于 2024 年 8 月 29 日在公司会议室以现场结合通讯的方式召开。会议应出席监事 3 人，实际出 席会议的监事 3 人，会议由监事会主席孟仲建先生主持。本次监事会会议的召集、 召开和表决程序符合有关法律、行政法规、部门规章、规范性文件和《公司章程》 的规定。经会议审议，全体监事审议通过了如下议案。 二、 监事会会议审议情况 （一）审议通过《关于 2024 年半年度报告及摘要的议案》 1、公司 2024 年半年度报告的编制和审议程序规范合法，符合法律、法规、 《公司章程》和公司内部管理制度的各项规定，内容真实、准确、完整。 2、公司 2024 年半年度报告的内容和格式符合中国证监会和上 ...